Key result
Sotatercept added to background therapy improves exercise capacity, hemodynamics, and risk status in PAH.
Why the study?
Despite advances in vasodilator therapies, many patients with PAH fail to achieve or maintain a low-risk profile, highlighting the need for disease-modifying strategies targeting pathways such as dysregulated TGF-β superfamily signalling.
Does sotatercept improve exercise capacity, haemodynamics, and risk status in patients with pulmonary arterial hypertension?
Does sotatercept improve exercise capacity, haemodynamics, and risk status in patients with pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
Sotatercept is a first-in-class activin signalling inhibitor that acts as a disease-modifying agent in pulmonary arterial hypertension, improving exercise capacity and hemodynamics.
Pulmonary arterial hypertension (PAH) is a severe, progressive vasculopathy characterized by endothelial dysfunction, medial hypertrophy, and maladaptive vascular and cardiac remodelling that ultimately leads to right-heart failure and premature death. Despite advances in vasodilator therapies targeting endothelin, nitric oxide, and prostacyclin pathways, a substantial proportion of patients fail to achieve or maintain a low-risk profile, highlighting the need for disease-modifying strategies. Dysregulation of transforming growth factor-β (TGF-β) superfamily signalling, with excessive activin and growth differentiation factor activity and impaired bone morphogenetic protein signalling, plays a central role in PAH pathobiology. Sotatercept, a first-in-class activin signalling inhibitor, restores this imbalance by selectively trapping pro-proliferative ligands, thereby addressing a key molecular driver of pulmonary vascular remodelling. Evidence from pivotal phase II and III trials—PULSAR, STELLAR, ZENITH, and HYPERION—demonstrates that sotatercept significantly improves exercise capacity, haemodynamics, and risk status when added to background therapy. This review summarises the molecular mechanisms underlying sotatercept’s therapeutic effects, synthesises the current clinical evidence, and discusses its emerging role as a disease-modifying agent capable of promoting reverse pulmonary vascular remodelling within contemporary PAH management.
No takes yet. Share an insight, caveat, or question.
Tilea et al. (2026) studied this question. Sotatercept significantly improved exercise capacity, haemodynamics, and risk status in pulmonary arterial hypertension patients when added to background therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: